Abstract The proton pump inhibitors are first-line drugs for the treatment of a number of gastrointestinal diseases. These drugs have a good safety profile, making it possible to use them in paediatric patients. Although their pharmacokinetics in children has not been extensively studied, research performed suggests that the dose used should be varied as a function of age, as this factor affects the drug's metabolism. Proton pump inhibitors can be used in critically ill children for the prophylaxis and treatment of gastrointestinal haemorrhage, although there is still little experience with this. The most widely used proton pump inhibitor at the present time is omeprazole. As there are specific characteristics of these patients that could alter the pharmacokinetics of the drugs, studies need to be performed to determine the most suitable dose and dosage interval.
Introduction
The proton pump inhibitors (PPI) are first-line drugs for the treatment of gastro-oesophageal reflux, gastroduodenal ulcer, and other digestive tract diseases [1] [2] [3] . A meta-analysis that included data from 569 critically ill patients demonstrated that PPIs were more effective than H2 receptor antagonists in reducing gastrointestinal haemorrhage, with a similar incidence of nosocomial pneumonia in the two groups [4] . In addition, the PPIs have a series of advantages over H2 receptor antagonists as they have a longer duration of action, inhibit both basal acid secretion and that occurring after parietal cell stimulation, and they do not produce tolerance [5] . Furthermore, they have a good safety profile, making their use possible in children [6] .
There are five PPIs: omeprazole, lansoprazole, pantoprazole, rabeprazole and esomeprazole. They differ in their molecular structure, giving rise to certain differences in their pharmacokinetics [6] (Table 1) .
Omeprazole was the first known PPI and has been widely used for more than two decades. It is usually administered by mouth; the intravenous presentation is reserved for the prophylaxis and treatment of critically ill patients, severe gastrointestinal haemorrhage, and patients in whom oral administration is contraindicated.
Mechanism of action and pharmacokinetics of the PPIs
The PPIs are benzimidazole derivatives that differ in their substitution patterns. They are basic compounds with a pKa of around 4.0 (except rabeprazole, with a pKa of 5), becoming activated when the pH of the medium is below their pKa [7] . The rate of conversion to the active form is inversely proportional to the pKa; rabeprazole is the PPI with the highest rate of conversion, followed by omeprazole, lansoprazole, and pantoprazole [5] .
After oral administration, the PPIs are absorbed as prodrugs in the small bowel and enter the gastric parietal cells, from where they reach the extracellular canaliculi. At this site, due to the acid medium, they are transformed into the active form which selectively and irreversibly binds the hydrogen/potassi-um exchange ATPase (H + /K + ATPase). The selectivity of the PPIs for the parietal cell is due to the fact that the ATPase is the only pump in the human body capable of generating a proton gradient greater than 1:1,000,000, achieving a pH of 0.8-1.0 within the parietal cell canaliculus [8] .
The formation of disulphide bridges between the PPI and cystine residues of the alpha subunit of the ATPase produces inhibition of acid secretion for up to 36 h [9] .
The proton pumps are in an inactive state in cytoplasm. After stimulation, such as a meal, the pump is translocated to the membrane of the canaliculus, where it is activated. To inhibit this, omeprazole must reach a sufficient plasma concentration. However, the duration of suppression of acid secretion does not depend on the peak concentration reached but on the area under the plasma concentration-time curve of the drug. The increase in the dose or the decrease in the dosage interval produces a non-linear increase in the area under the curve (AUC) of omeprazole. This fact is due to the slower clearance and the effect of the hepatic metabolism [9] .
Metabolism of the PPIs
Omeprazole and the other PPIs are metabolized in the liver by cytochrome P450. The principal enzymes involved in their metabolism are CYP2C19 and, to a lesser degree, CYP3A4, which transform omeprazole into the metabolites 5-hydroxyomeprazole and omeprazole sulphone; 80% of these metabolites are excreted in the urine.
As demonstrated by Kearns et al., there is marked genetic polymorphism of CYP2C19, which directly affects the pharmacokinetics of omeprazole and the other PPIs [10] .
Patients can be divided into three groups according to CYP2C19 polymorphism: homozygous extensive metabolizers, heterozygous extensive metabolizers, and poor metabolizers. Extensive metabolizers have a lower AUC than poor metabolizers and therefore require higher doses of omeprazole to achieve adequate suppression of acid secretion. Furthermore, there is a higher rate of nonresponders among extensive metabolizers [9] .
Furuta et al. found a significant correlation between the mean intragastric pH and the AUC of omeprazole. They also demonstrated an association between the CYP2C19 phenotype and the pharmacokinetics and pharmacodynamics of omeprazole, with extensive metabolizers presenting a lower AUC than the poor metabolizers [11] .
A variant of the CYP2C19 has recently been discovered, allele CYP2C19*17, which affects the metabolism of the PPIs, giving its carriers an extensive-metabolizer phenotype. This variant shows racial variations, being found in 18% of the Swiss and Ethiopian populations and in only 4% of the Chinese population [9, 12] .
The metabolism of omeprazole can also be affected by other drugs that inhibit CYP2C19 and CYP3A4, such as fluconazole and fluvoxamine [9] , and PPIs can interfere with the hepatic elimination of other drugs such as diazepam, carbamazepine, phenytoin, warfarin, and digoxin [13] .
Secondary effects of omeprazole
Short-term safety of omeprazole has been well established. It has a wide safety profile with rare and mild adverse reactions such as headache, diarrhoea, abdominal 
pain and nausea, and it is only contraindicated if the patient has a known history of hypersensitivity to it [3] . Although omeprazole is metabolized in the liver, it can be used with caution in patients with hepatic dysfunction as it does not cause direct toxicity and it does not need renal adjustment.
Pharmacokinetics of omeprazole in children
The immaturity of various organ systems leads to differences in the pharmacokinetics and efficacy of the PPIs in children compared to adults.
Gastric secretion and motility in children
The embryonic development of the stomach is completed between weeks 14 and 15 of gestation. The mass of parietal cells is responsible for acid secretion and increases with increasing weight and gestational age. H + /K + ATPase is present by week 25 of gestation and its expression increases with age. Premature infants born after week 24 of gestation are therefore able to maintain an intragastric pH below 4 from the first day of life [7, 14] . Although gastric pH in the newborns is slightly higher than in adults, their maximum acid secretion is similar [14] .
Gastric emptying and intestinal motility vary with age, affecting rates of drug absorption [15] . Neonates have slower gastric emptying, and lower motility, leading to a greater absorption of drugs in the neonatal age range [16] .
Distribution of PPIs in children
The distribution of PPIs can be different in children as factors such as tissue perfusion, the concentration of plasma proteins, and body composition vary with age [15, 17] .
Newborn infants have a higher percentage of water and smaller quantity of fat in the body, increasing the volume of distribution (Vd) of water-soluble substances. Studies performed in paediatric patients found that children have a higher Vd than adults after a single dose of omeprazole but that the Vd after repeated doses is similar in the two age groups [7, 18] .
Albumin, α1-glycoprotein, and the lipoproteins are the most important systems to which drugs bind; basic compounds show affinity for albumin and lipoproteins, whereas acidic and neutral compounds have a higher affinity for albumin. Protein concentrations vary with age (infants have lower levels and reach adult levels at 10-12 months of age), nutrition, and disease [15] . The significance of protein levels derives from the fact that only the free drug, that is, the non-protein-bound drug, reaches the tissues, binds to the receptor, and induces a response [16] . In addition, the strong plasma proteinbinding of the PPIs delays their elimination [17] .
The bioavailability of omeprazole can also be affected by immaturity of the parietal cells, and it can impede accumulation of the active form of the PPIs within the canaliculus of the parietal cell [6] .
Metabolism of PPI in children
Hepatic and renal functions also vary with age, affecting drug metabolism and elimination. At birth, there is a low level of activity of the enzymes CYP2C19 and CYP3A4; adult levels of activity are reached in early childhood [19] . At 2 years of age, children have a greater oxidative capacity than adults, whereas glucuronidation develops more slowly. As children approach puberty, their metabolism becomes more similar to that of adults [20] . Premature and newborn infants present a lower level of elimination of metabolites, favouring accumulation, whereas this is uncommon in older infants and in children [20] .
Pharmacokinetics of omeprazol in children
Paediatric studies on the pharmacokinetics of omeprazole have been performed mainly in children over 2 years of age, and there are still insufficient data in younger children [7] .
The pharmacokinetics of oral omeprazole in children of different age groups (between 1 and 16 years) were evaluated in a multicentre study performed by Andersson et al. [21] ; the authors reached the conclusion that the pharmacokinetic parameters were mainly in the adult range, although there was a higher metabolic activity in the 1-to 6-year-old group. A later study performed by the same author [22] evaluated the pharmacokinetics of intravenous omeprazole in neonates and infants, observing that neonates presented a longer half-life and clearance than infants, which could be explained by the low CYP2C19 and CYP3A4 activity present at birth. This suggests that, as drug metabolism varies with age, the dose of omeprazole should also be different depending on the age group to which it is being administered.
In children, as in adults, there is a significant interindividual pharmacokinetic variability due in part to polymorphism of CYP2C19. As reviewed by Kearns et al., the poor metabolizer phenotype for CYP2C19 is produced by the inheritance of two recessive mutated alleles. The two most common variants, CYP2C19*2 and CYP2C19*3, are responsible for a decrease in the enzyme activity [10] . This implies increased plasma concentrations and AUC.
Studies performed by Zimmerman et al. also suggest the existence of interindividual variability in the effective dose of omeprazole in paediatric patients [13] , whereas other authors consider that the bioavailability of omeprazole can be determined both by CYP2C19 activity and by age [19] . Marier et al. compared the pharmacokinetic parameters of oral omeprazole in children with gastro-oesophageal reflux disease (GERD) with those in healthy adults [15] . Those authors found that the clearance and volume of distribution were similar for the two age groups, with a greater delay in drug absorption in adults. They therefore recommended that the dose in children with GERD should be calculated in milligrams per kilogram body weight and that no other adjustments were necessary [15] .
There are very few studies of the pharmacokinetics of intravenous omeprazole in children ( Table 2 ). The first study was performed by Jacqz-Aigrain et al. in 1994 in 13 patients of different ages and with different diseases. As occurred with oral administration, the pharmacokinetic parameters were similar to those of adults, with an interindividual variability secondary to hepatic and renal function and concomitant treatment [23] .
Andersson et al. studied eight patients, aged 8 days to 17 months, receiving intravenous omeprazole at doses of 0.4-1.2 mg/kg. They found that in children ≤10 days, the t 1/2 and clearance of omeprazole were 1.6-2.1 h and 0.12-0.20 L h −1 kg −1 respectively, substantially longer and lower than the corresponding values in children aged 4.5-17 months and in adults reported previously. These t 1/2 and clearance values were closer to those previously reported in poor metabolizers (PM) with regard to CYP2C19. These results suggest that CYPs 2C19 and 3A4 are not fully mature at this young age while in children aged 4.5-17 months, the metabolism rate seems to be within the range reported in adults [22] . Faure et al. studied the pharmacokinetics and optimum dose of intravenous omeprazole in nine patients under 30 months of age. The patients were divided into two groups; the first group received 20 mg/1.73 m 2 and the second 40 mg/1.73 m 2 , once a day. The authors demonstrated that a dose of 40 mg/1.73 m 2 was necessary to maintain a pH above 4 for 24 h [24] .
Further studies are necessary to investigate the pharmacokinetics of intravenous omeprazole in different age groups and under different conditions during childhood. For this reason it is difficult to assess an optimum dose and interval of administration. Table 3 shows the recommendations suggested by different authors.
PPI treatment in critically ill patients
In critical patients acid secretion is induced by gastrine or histamine released by stress. This acid secretion injures the gastric mucous producing digestive bleeding. Critically ill adult and paediatric patients are at high risk OR Oral route, iv intravenous route, bid twice daily, GERD gastroesophageal reflux disease of gastrointestinal haemorrhage; this event increases morbidity and mortality. Mechanical ventilation for more than 48 h, coagulation disorders, shock, neurosurgery, respiratory failure and sepsis are factors that increase the risk of gastrointestinal haemorrhage [25] . Prophylaxis for gastrointestinal haemorrhage is therefore recommended in critically ill children and adults. The most widely used drugs for prophylaxis are the H2 receptor antagonists and the PPIs [4, 25, 26] .
Pharmacokinetics of omeprazole in critically ill patients
Critically ill patients have pharmacokinetic characteristics that affect drug absorption, metabolism, bioavailability, and excretion. The pharmacokinetic changes are due to organ dysfunction (particularly hepatic and renal), the release of acute-phase reactants, interactions with other drugs, and therapeutic interventions.
The absorption of drugs in patients in intensive care depends on the chemical characteristics of the compound and the form of administration. Factors such as molecular size, solubility, degree of fat solubility, pKa and stability of the substances affect absorption, though properties of the medium in which the drug is administered (pH, gastrointestinal motility and blood flow) are also relevant [27] .
In critically ill patients, the oral absorption of drugs is affected by the reduction in intestinal motility, which is of multifactorial origin and is very common in these patients [27] . Furthermore, hypoperfusion and fasting lead to the appearance of intestinal atrophy and alterations of enzyme activity, further exacerbating gastrointestinal dysfunction [28, 29] . These factors can lead to an abnormal absorption of drugs after oral administration, making intravenous administration the route of choice.
Drug distribution in critically ill patients depends on many factors, including organ perfusion, plasma protein binding, tissue permeability, fat solubility of the substances, pH of the medium, and pKa of the drug [27] .
Hypoalbuminaemia and a rise in fatty acid concentrations are common in critically ill patients [27, 30, 31] . This decrease in the albumin concentration increases the free fraction of those drugs that are strongly protein bound, such as omeprazole. There are other drugs, such as lidocaine, which show affinity for and bind to fatty acids. This means that when the concentration of fatty acids rises, the free fraction of some drugs and, hence, the amount of active drug will fall [31] .
Finally, changes in the pH of the blood can also affect drug distribution by altering ionisation [27] .
Critically ill patients very often present organ dysfunction, particularly of the hepatic and renal systems, altering drug bioavailability. Hepatic blood flow affects drug metabolism by increasing or decreasing the quantity of drug reaching the hepatocyte. Hypovolaemia, haemorrhage and heart failure, as well as treatment with alpha-agonists, reduce hepatic blood flow, producing a fall in drug clearance [32] . In contrast, vasodilators favour clearance by reducing vascular resistances [27] .
In critically ill patients, the release of inflammatory cytokines [interleukin (IL) 6, tumour necrosis factor] and of stress hormones (adrenaline, noradrenaline and cortisol) produces an inhibition of cytochrome P450 (phase I of hepatic metabolism), altering the metabolism of all substances dependent on this enzyme, including omeprazole. Phase II of hepatic metabolism (conjugation) is also affected, though to a lesser extent [27, 33] .
In addition, interactions that occur between drugs as a consequence of multiple treatments can also affect PPI metabolism.
Although omeprazole is metabolised in the liver, it can be used in patients with hepatic dysfunction as it does not cause direct toxicity. However, the presence of CYP2C19 polymorphisms must be taken into account as these can increase blood levels and affect acid suppression, drug efficacy, and interactions with other drugs.
There are few data on the pharmacokinetics of intravenous omeprazole in critically ill patients even though this is the route of administration of choice in these patients. Studies performed by Cedeberg in adults demonstrated that the administration of intravenous omeprazole is more effective than oral administration, requiring a lower dose to achieve the same effect [34, 35] .
Piqué et al. studied the pharmacokinetics of intravenous omeprazole in 30 patients with different degrees of hepatic dysfunction secondary to cirrhosis, observing an AUC of 286.5 µmol·h/L, a peak plasma concentration of 14.9 µmol/L, and a half-life of 4.1 h. All these values were higher than in patients with normal liver function, although the drug was well tolerated by all patients [36] .
Another study performed on patients with a high risk of bleeding ulcer compared the benefits of high doses of Litalien et al. [7] 1 mg/kg iv once daily Zimmerman [13] 1 mg/kg OR once daily in children with GERD and esophagitis Faure et al. [24] 40 mg/1.73 m 2 iv once daily or bid in critical paediatric patients Kaufman et al. [40] In most patients a dosage of 0.5 mg kg
is sufficient to maintain pH > 4 but dosing every 6-8 h is required to assure acid suppression in all iv Intravenous, OR oral route, bid twice daily intravenous omeprazole with the standard dose [37] . The study was performed on 114 patients and was divided into two periods, the first before 2001, in which a dose of 40 mg/day was administered intravenously, followed by 40 mg/day by mouth when feeding was restarted, and the second period, from 2001, in which patients were administered an intravenous bolus of 80 mg followed by an infusion of 8 mg/h for 72 h, after which the dose was changed to 40 mg/day by mouth. The results showed that high doses of intravenous omeprazole reduced the onset of bleeding, the need for surgery, and mortality due to haemorrhagic shock in patients with a high risk of gastrointestinal haemorrhage due to peptic ulceration.
Omeprazole treatment in critically ill children
Critically ill children have an increased risk of gastrointestinal haemorrhage secondary to acute lesions of the gastroduodenal mucosa; this risk increases with the severity of the clinical state [38, 39] . Gastrointestinal haemorrhage occurring in situations of stress is secondary to ischemia of the superficial mucosa, which reduces the secretion of bicarbonate and mucus, making the gastric mucosa more vulnerable to acid secretion [40] . As in adults, prophylaxis against gastrointestinal haemorrhage is indicated in critically ill children with risk factors [26] . The objective is to achieve an intragastric pH above 4.
The most important factors that increase the risk of gastrointestinal haemorrhage are mechanical ventilation and coagulopathy [41] . Other factors are sepsis, renal and liver failure, corticoids and low platelet count [42] .
For these reasons, omeprazole should be started inmediately in paediatric critical patients with risk factors for gastrointestinal bleeding.
Pharmacokinetics of omeprazol in critically ill paediatric patients
Critically ill paediatric patients also present alterations that affect the absorption, bioavailability, metabolism and elimination of omeprazole. Hypoperfusion and altered intestinal motility produce an erratic absorption of omeprazole when it is administered orally [27] . This means that, as in adults, it would be preferable to administer the drug intravenously in critically ill children. There are very few data on the pharmacokinetics of intravenous omeprazole in critically ill paediatric patients [22, 40] .
A fall in the concentration of plasma proteins is common in the critically ill child and produces a fall in oncotic pressure and an increase in vascular permeability, leading to capillary volume loss into the interstitium, with expansion of the extracellular volume or third space. This expansion of the extracellular volume particularly affects the volume of distribution of water-soluble substances, whereas that of fat-soluble substances remains almost unchanged [28, 43] .
The metabolism of omeprazole has not been studied in paediatric patients with liver dysfunction, although it is to be expected that the results would be similar to those of adults, with a reduction in its clearance. There is only one case reported in a child of 5 years of age with liver dysfunction: clearance was found to be slower and there was an increase in the half-life of the drug [23] . However, no change has been detected in omeprazole excretion in patients with renal dysfunction.
Children with systemic inflammatory response syndrome (SIRS) present a similar pharmacokinetic situation to that of poor metabolizers, with a slower clearance, larger AUC and longer half-life compared to children without SIRS or to healthy adults. This is probably due to the effect of cytokines on the regulation of CYP isoforms [7] .
Kaufman et al. performed a study in 22 paediatric patients who had undergone liver or intestinal transplant, demonstrating that the administration of intravenous omeprazole is effective for the suppression of acid secretion in these patients. A dose of 0.5 mg kg −1 12 h −1 was sufficient for many patients, though administration every 6-8 h was necessary in order to achieve maximum acid suppression [40] . These patients also presented a slower elimination and longer half-life; this could have been due not only to slowing of the metabolism caused by liver dysfunction but also to the effect of cytokines and inflammation [7] . Pettersen et al. studied the pharmacokinetics of pantoprazole in 20 critically ill paediatric patients between 10 days and 16.4 years of age. Those authors found that the clearance of pantoprazole increased with increasing weight and age, and fell with the presence of SIRS, CYP2C19 inhibitors, and liver dysfunction. However, in patients between 6 months and 5 years of age without these factors, pantoprazole clearance was higher than in adults [44] .
In summary, PPIs are drugs with a sufficient safety profile to permit their use in paediatric patients. Omeprazole is the most widely used drug in the paediatric population. Although there is little experience, these drugs can be used in critically ill children for the prophylaxis and treatment of gastrointestinal haemorrhage. However, as these patients present specific characteristics that can alter the pharmacokinetics of these drugs, studies need to be performed to determine the most suitable dose and dosage interval.
Practical recommendations
Although the dose and interval of intravenous omeprazole has not been clearly established in critically ill paediatric patients, we recommend beginning with a dose of 0.5-1 mg kg −1 12 h −1 in critically ill children with gastrointestinal bleeding risk factors, especially mechanical ventilation and coagulopathy, and maintaining this dose during the critical situation. Pharmacokinetics studies are necessary to analyse the most adequate omeprazole dose and interval in critically ill children.
